Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Estrogen Receptor alpha | 6 | 2019 | 40 | 1.92 | Why? |
| Selective Estrogen Receptor Modulators | 5 | 2019 | 65 | 1.23 | Why? |
| Cell Nucleus | 4 | 2018 | 399 | 0.98 | Why? |
| Insulin Resistance | 3 | 2018 | 669 | 0.93 | Why? |
| Estrogens | 4 | 2018 | 252 | 0.83 | Why? |
| Apelin Receptors | 1 | 2017 | 8 | 0.72 | Why? |
| Cell Membrane | 3 | 2018 | 743 | 0.70 | Why? |
| Apelin | 1 | 2017 | 41 | 0.69 | Why? |
| Receptors, Estrogen | 1 | 2018 | 171 | 0.67 | Why? |
| Anti-Obesity Agents | 1 | 2017 | 52 | 0.67 | Why? |
| Liraglutide | 1 | 2017 | 47 | 0.66 | Why? |
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 245 | 0.58 | Why? |
| Diabetes Mellitus, Type 2 | 10 | 2021 | 6166 | 0.53 | Why? |
| Sex Characteristics | 1 | 2021 | 1120 | 0.50 | Why? |
| Fatty Liver | 1 | 2017 | 299 | 0.50 | Why? |
| Energy Metabolism | 1 | 2017 | 451 | 0.48 | Why? |
| Myocytes, Cardiac | 1 | 2018 | 804 | 0.45 | Why? |
| Diabetes Mellitus | 4 | 2021 | 8207 | 0.45 | Why? |
| Overweight | 1 | 2017 | 916 | 0.43 | Why? |
| Hypoglycemic Agents | 3 | 2020 | 2165 | 0.43 | Why? |
| Medicine | 1 | 2017 | 485 | 0.40 | Why? |
| Blood Glucose | 2 | 2020 | 3642 | 0.26 | Why? |
| Obesity | 3 | 2020 | 7388 | 0.24 | Why? |
| Diet, High-Fat | 2 | 2017 | 161 | 0.19 | Why? |
| Lipomatosis, Multiple Symmetrical | 1 | 2018 | 4 | 0.19 | Why? |
| PPAR alpha | 1 | 2019 | 36 | 0.19 | Why? |
| Glucose | 2 | 2020 | 573 | 0.19 | Why? |
| Estrogen Replacement Therapy | 1 | 2019 | 50 | 0.19 | Why? |
| Liver | 3 | 2019 | 4007 | 0.19 | Why? |
| GTP Phosphohydrolases | 1 | 2018 | 89 | 0.18 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.18 | Why? |
| Glucose Clamp Technique | 1 | 2017 | 39 | 0.18 | Why? |
| Lysophosphatidylcholines | 1 | 2017 | 5 | 0.18 | Why? |
| Active Transport, Cell Nucleus | 1 | 2018 | 203 | 0.17 | Why? |
| Mice, Knockout | 3 | 2018 | 1815 | 0.17 | Why? |
| Ovariectomy | 1 | 2017 | 53 | 0.17 | Why? |
| Mitochondrial Proteins | 1 | 2018 | 152 | 0.17 | Why? |
| Signal Transduction | 4 | 2018 | 7207 | 0.17 | Why? |
| Menopause | 1 | 2019 | 136 | 0.17 | Why? |
| Hormone Replacement Therapy | 1 | 2018 | 146 | 0.16 | Why? |
| Mice, Inbred C57BL | 5 | 2019 | 5542 | 0.16 | Why? |
| Lysophospholipids | 1 | 2017 | 74 | 0.16 | Why? |
| Tamoxifen | 1 | 2017 | 83 | 0.16 | Why? |
| Inpatients | 6 | 2021 | 5161 | 0.16 | Why? |
| Periodontitis | 1 | 2018 | 171 | 0.16 | Why? |
| Insulin-Secreting Cells | 1 | 2018 | 273 | 0.15 | Why? |
| Arteries | 1 | 2018 | 283 | 0.15 | Why? |
| Body Mass Index | 2 | 2020 | 4306 | 0.15 | Why? |
| Adaptation, Physiological | 1 | 2019 | 359 | 0.15 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2021 | 436 | 0.15 | Why? |
| Glycated Hemoglobin A | 3 | 2020 | 1316 | 0.15 | Why? |
| Proof of Concept Study | 1 | 2017 | 696 | 0.14 | Why? |
| France | 3 | 2021 | 12074 | 0.14 | Why? |
| Cross-Over Studies | 1 | 2017 | 867 | 0.13 | Why? |
| Triglycerides | 1 | 2017 | 478 | 0.13 | Why? |
| Aortic Diseases | 1 | 2018 | 362 | 0.13 | Why? |
| Metformin | 1 | 2020 | 640 | 0.13 | Why? |
| Diabetic Nephropathies | 1 | 2017 | 315 | 0.13 | Why? |
| Medication Therapy Management | 1 | 2017 | 312 | 0.13 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.12 | Why? |
| Adipose Tissue | 1 | 2018 | 612 | 0.12 | Why? |
| Homeostasis | 1 | 2017 | 582 | 0.12 | Why? |
| Diabetes Complications | 2 | 2021 | 2358 | 0.12 | Why? |
| Weight Gain | 1 | 2017 | 552 | 0.12 | Why? |
| Animals | 10 | 2019 | 78931 | 0.10 | Why? |
| Prognosis | 7 | 2021 | 32490 | 0.10 | Why? |
| Atherosclerosis | 1 | 2018 | 768 | 0.10 | Why? |
| Structure-Activity Relationship | 1 | 2017 | 2219 | 0.10 | Why? |
| Renal Insufficiency | 1 | 2017 | 810 | 0.10 | Why? |
| Dyslipidemias | 1 | 2016 | 791 | 0.10 | Why? |
| Hyperglycemia | 1 | 2020 | 1363 | 0.10 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.09 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 1510 | 0.09 | Why? |
| Diabetes Mellitus, Type 1 | 2 | 2020 | 1969 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.09 | Why? |
| Patient Discharge | 2 | 2021 | 5696 | 0.09 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.08 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.08 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.08 | Why? |
| Protein Conformation | 1 | 2017 | 4386 | 0.08 | Why? |
| Respiration, Artificial | 5 | 2021 | 22116 | 0.07 | Why? |
| Drug Evaluation, Preclinical | 1 | 2017 | 3347 | 0.07 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.07 | Why? |
| Humans | 23 | 2021 | 930598 | 0.07 | Why? |
| Patient Satisfaction | 1 | 2017 | 2517 | 0.07 | Why? |
| Female | 15 | 2021 | 380317 | 0.07 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.07 | Why? |
| Male | 14 | 2021 | 367725 | 0.06 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.06 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2021 | 17020 | 0.06 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.06 | Why? |
| Propensity Score | 2 | 2021 | 2690 | 0.06 | Why? |
| Disease Models, Animal | 2 | 2018 | 10998 | 0.06 | Why? |
| Sepsis | 1 | 2019 | 3517 | 0.06 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.05 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.05 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Root Planing | 1 | 2018 | 2 | 0.05 | Why? |
| SOX9 Transcription Factor | 1 | 2018 | 43 | 0.05 | Why? |
| Estetrol | 1 | 2018 | 1 | 0.05 | Why? |
| Aged | 9 | 2021 | 215776 | 0.05 | Why? |
| Dental Scaling | 1 | 2018 | 21 | 0.05 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.05 | Why? |
| Receptors, LDL | 1 | 2018 | 42 | 0.05 | Why? |
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 96 | 0.04 | Why? |
| Vascular Remodeling | 1 | 2018 | 99 | 0.04 | Why? |
| Phenotype | 2 | 2021 | 4037 | 0.04 | Why? |
| Calibration | 1 | 2019 | 307 | 0.04 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.04 | Why? |
| Nod1 Signaling Adaptor Protein | 1 | 2017 | 23 | 0.04 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.04 | Why? |
| Nod2 Signaling Adaptor Protein | 1 | 2017 | 39 | 0.04 | Why? |
| Fatty Acids | 1 | 2019 | 238 | 0.04 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.04 | Why? |
| Renal Elimination | 1 | 2017 | 62 | 0.04 | Why? |
| Estradiol | 1 | 2018 | 250 | 0.04 | Why? |
| Nerve Tissue Proteins | 1 | 2018 | 319 | 0.04 | Why? |
| Albuminuria | 1 | 2017 | 164 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Genotype | 2 | 2017 | 4697 | 0.04 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
| Lipopolysaccharide Receptors | 1 | 2017 | 357 | 0.03 | Why? |
| Mice | 3 | 2019 | 21357 | 0.03 | Why? |
| Plaque, Atherosclerotic | 1 | 2018 | 423 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Hepatocytes | 1 | 2017 | 549 | 0.03 | Why? |
| Positron-Emission Tomography | 1 | 2018 | 802 | 0.03 | Why? |
| Lipopolysaccharides | 1 | 2017 | 848 | 0.03 | Why? |
| History, 20th Century | 1 | 2018 | 1282 | 0.03 | Why? |
| Prospective Studies | 1 | 2017 | 43301 | 0.03 | Why? |
| Adult | 3 | 2018 | 244371 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2017 | 1262 | 0.03 | Why? |
| History, 21st Century | 1 | 2018 | 1849 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2017 | 2739 | 0.03 | Why? |
| Treatment Outcome | 1 | 2017 | 51732 | 0.03 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.02 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.02 | Why? |
| Blood Pressure | 1 | 2018 | 2198 | 0.02 | Why? |
| Adolescent | 1 | 2017 | 86841 | 0.02 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.02 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Bacterial Infections | 1 | 2019 | 2229 | 0.02 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.02 | Why? |
| RNA, Messenger | 1 | 2018 | 5131 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Inflammation | 1 | 2019 | 13255 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
Gourdy's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(157)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(124)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_